Rachel F Buckley1, Paul Maruff2, David Ames3, Pierrick Bourgeat4, Ralph N Martins5, Colin L Masters6, Stephanie Rainey-Smith7, Nicola Lautenschlager8, Christopher C Rowe9, Greg Savage10, Victor L Villemagne11, Kathryn A Ellis3. 1. Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia. Electronic address: rachel.buckley@unimelb.edu.au. 2. Cogstate Ltd, Melbourne, Australia. 3. The Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry, University of Melbourne. 4. The Australian eHealth Research Centre, CSIRO Health & Biosecurity Flagship, QLD, Australia. 5. Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, WA, Australia; School of Psychiatry and Clinical Neurosciences and West Australian Centre for Health & Ageing, University of Western Australia; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia. 6. The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia. 7. Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, WA, Australia; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia. 8. The Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry, University of Melbourne; School of Psychiatry and Clinical Neurosciences and West Australian Centre for Health & Ageing, University of Western Australia. 9. Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia; Department of Medicine, Austin Health, University of Melbourne, Melbourne, Australia. 10. ARC Centre of Excellence in Cognition and its Disorders, Macquarie University, Sydney, Australia. 11. The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia; Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia; Department of Medicine, Austin Health, University of Melbourne, Melbourne, Australia.
Abstract
INTRODUCTION: The objective of this study was to determine the utility of subjective memory decline (SMD) to predict episodic memory change and rates of clinical progression in cognitively normal older adults with evidence of high β-amyloid burden (CN Aβ+). METHODS: Fifty-eight CN Aβ+ participants from the Australian Imaging, Biomarkers, and Lifestyle study responded to an SMD questionnaire and underwent comprehensive neuropsychological assessments. Participant data for three follow-up assessments were analyzed. RESULTS: In CN Aβ+, subjects with high SMD did not exhibit significantly greater episodic memory decline than those with low SMD. High SMD was related to greater rates of progression to mild cognitive impairment or Alzheimer's disease (AD) dementia (hazard ratio = 5.1; 95% confidence interval, 1.4-20.0, P = .02) compared with low SMD. High SMD was associated with greater depressive symptomatology and smaller left hippocampal volume. DISCUSSION: High SMD is a harbinger of greater rates of clinical progression in preclinical AD. Although SMD reflects broader diagnostic implications for CN Aβ+, more sensitive measures may be required to detect early subtle cognitive change.
INTRODUCTION: The objective of this study was to determine the utility of subjective memory decline (SMD) to predict episodic memory change and rates of clinical progression in cognitively normal older adults with evidence of high β-amyloid burden (CN Aβ+). METHODS: Fifty-eight CN Aβ+ participants from the Australian Imaging, Biomarkers, and Lifestyle study responded to an SMD questionnaire and underwent comprehensive neuropsychological assessments. Participant data for three follow-up assessments were analyzed. RESULTS: In CN Aβ+, subjects with high SMD did not exhibit significantly greater episodic memory decline than those with low SMD. High SMD was related to greater rates of progression to mild cognitive impairment or Alzheimer's disease (AD) dementia (hazard ratio = 5.1; 95% confidence interval, 1.4-20.0, P = .02) compared with low SMD. High SMD was associated with greater depressive symptomatology and smaller left hippocampal volume. DISCUSSION: High SMD is a harbinger of greater rates of clinical progression in preclinical AD. Although SMD reflects broader diagnostic implications for CN Aβ+, more sensitive measures may be required to detect early subtle cognitive change.
Authors: José L Molinuevo; Laura A Rabin; Rebecca Amariglio; Rachel Buckley; Bruno Dubois; Kathryn A Ellis; Michael Ewers; Harald Hampel; Stefan Klöppel; Lorena Rami; Barry Reisberg; Andrew J Saykin; Sietske Sikkes; Colette M Smart; Beth E Snitz; Reisa Sperling; Wiesje M van der Flier; Michael Wagner; Frank Jessen Journal: Alzheimers Dement Date: 2016-11-05 Impact factor: 21.566
Authors: Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber Journal: World J Biol Psychiatry Date: 2017-10-27 Impact factor: 4.132
Authors: Rachel F Buckley; Bernard Hanseeuw; Aaron P Schultz; Patrizia Vannini; Sarah L Aghjayan; Michael J Properzi; Jonathan D Jackson; Elizabeth C Mormino; Dorene M Rentz; Reisa A Sperling; Keith A Johnson; Rebecca E Amariglio Journal: JAMA Neurol Date: 2017-12-01 Impact factor: 18.302
Authors: Jacob W Vogel; Monika Varga Doležalová; Renaud La Joie; Shawn M Marks; Henry D Schwimmer; Susan M Landau; William J Jagust Journal: Neurology Date: 2017-10-06 Impact factor: 9.910